Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A patient with comorbid intellectual disability, catatonic schizophrenia, and recurrent oneiroid state of consciousness improved on long-acting risperidone and remains well at the three-year follow-up. We report a case treated with 50 mg long-acting risperidone administered every 14 days, who has been followed-up for three years. We studied his regional cerebral blood flow through technetium-99 m hexamethylpropyleneamine oxime single-photon emission computed tomography after two years of treatment. Symptoms of catatonic schizophrenia improved after two months of treatment, followed suit by oneiroid syndrome remission. Two years later, his brain perfusion was normal. No side effect has occurred since the patient was started on long-acting risperidone. Long-acting risperidone proved to be safe and effective in treating symptoms of catatonia and oneiroid syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0091217415610512 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies.
Adv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.
J Clin Psychopharmacol
September 2025
LVR Institute for Research and Education, Department of Research.
Background: The objective of this study was to characterize real-world prescription patterns of antipsychotic drugs in patients with various psychiatric disorders with psychotic features.
Method: We analyzed the discharge prescription plans of 59,962 cases with the main diagnoses schizophrenia, schizoaffective disorder, acute transient psychotic disorder, delusional disorder, psychotic bipolar disorder, psychotic depression, organic delusional disorder or substance-induced psychosis. We analyzed the overall use, pharmacological subgroups, the use of long-acting injectable (LAI) formulations, and the frequency of prescription of the singular antipsychotic drugs.
QT interval prolongation from antipsychotics in schizophrenia and acute psychosis - A prospective study.
Ind Psychiatry J
July 2025
Department of Psychiatry, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Background: Antipsychotic drugs have the potential to cause QT-interval prolongation (QTIP), which may lead to Torsades de Pointes and sudden cardiac death. Thus, it is important to know about the incidence and risk factors for QTIP.
Aim: The primary objective of the study was to find out the incidence of QTIP due to the use of antipsychotic drugs in patients with schizophrenia and acute psychosis after two weeks of drug use.
The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment.
Expert Opin Pharmacother
September 2025
Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Introduction: A key challenge in managing schizophrenia is ensuring adequate adherence to antipsychotic treatment. Long-acting injectable (LAI) antipsychotics play a crucial role in improving adherence, yet certain clinical needs remain unmet, including a rapid symptom control and satisfactory efficacy/tolerability balance.
Areas Covered: Main pharmacokinetics and pharmacodynamics properties as well as the effectiveness and safety profile of risperidone in situ microparticles (ISM®) are described.
Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients.
Schizophr Res
August 2025
Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, United States of America; Department of Psychology, University of California, Los Angeles, United States of America.
Black and Latino Americans are more likely to be diagnosed with psychotic disorders compared to White Americans. Furthermore, there are well documented ethnoracial disparities in access to second-generation antipsychotics including long-acting injectables (LAIs). LAI medications have the potential to help attenuate disparities by improving adherence and thus reducing relapse.
View Article and Find Full Text PDF